Recombinant Human Serpin E1/PAI-1 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3798

---

Validation Data Gallery

• 

  Purity of Recombinant Human Serpin E1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human Serpin E1 protein Val24-Pro402 (Accession# P05121-1) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 5054
• Accession: P05121-1
• PredictedSize: 70.0 kDa
• SDS-PAGE: 65-75 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

SERPINE1, also named as Plasminogen activator inhibitor type 1 (PAI-1), is a member of the serine protease inhibitor (SERPIN) superfamily. It is produced by the vascular endothelium, the liver, the monocytes/macrophagues, the platelets and the adipose tissue. High plasma levels of PAI-1 have been associated with an increased risk of suffering cardiovascular diseases. It is implicated in the pathogenesis of obesity, insulin resistance and type 2 diabetes. In several tumor types, SERPINE1 expression is up-regulated and it has been described as a poor prognostic marker. Besides its prognostic value, SERPINE1 expression has been validated as a marker for therapy decision making in patients with node-negative breast cancer. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia.

References:

1. Huang J. et al.(2012). Blood. 20: 4873-81.
2. Kohler HP. et al. (2000). N Engl J Med. 342: 1792-801.
3. Festa A. et al. (2006). Circulation. 113: 1753-9.
4. Look MP. et al. (2002). J Natl Cancer Inst. 16;94(2):116-28.
5. Ulisse S. et al. (2009). Curr Cancer Drug Targets. 9(1):32-71.